Ground News

See every side of every news story

ajmc.com image

News from ajmc.com

See all of ajmc.com news coverage in one place. Discover how ajmc.com’s media bias informs their coverage and compare with thousands of other news outlets.

We’ve aggregated 917 of ajmc.com’s headlines and news stories over the past 3 months.

ajmc.com’s aggregated media bias check is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

ajmc.com’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about ajmc.com

Where is ajmc.com located?ajmc.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top ajmc.com News

US FDA approves Gilead's twice-yearly injection for HIV prevention

HIV · United States

US FDA approves Gilead's twice-yearly injection for HIV prevention

65% Center coverage: 226 sources

The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported Wednesday. In clinical trials, the drug nearly eliminated HIV’s spread among people given an injection every six months. See the Story

All states, territories agree to $7.4B Purdue Pharma opioid settlement

Purdue Pharma · United States

All states, territories agree to $7.4B Purdue Pharma opioid settlement

63% Center coverage: 200 sources

The attorneys general of all 50 states, Washington D.C., and four territories have agreed to sign on to a $7.4 billion settlement with Purdue Pharma and the members of the Sackler family who own the company. See the Story

FDA Approves Once-Monthly Hereditary Angioedema Drug

FDA · United States

FDA Approves Once-Monthly Hereditary Angioedema Drug

62% Center coverage: 32 sources

Anti-factor XIIa biologic garadacimab (Andembry) got the FDA greenlight for use in preventing hereditary angioedema (HAE) attacks in adult and pediatric patients ages 12 years and older, CSL announced.See the Story

Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection

75% Center coverage: 4 sources

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jun 18, 2025-European Union · United States See the Story

Dupilumab for Atopic Dermatitis Linked to Increased Risk of Psoriasis

55% Center coverage: 22 sources

(MedPage Today) -- The use of dupilumab (Dupixent) for the treatment of atopic dermatitis was associated with an increased risk of psoriasis compared with other systemic agents, according to a retrospective cohort study. Among over 19,000 matched...Healthcare · United States See the Story

CARTITUDE-4 Data Solidify Cilta-cel’s Role in RRMM: Surbhi Sidana, MD, MBBS

Surbhi Sidana, MD, MBBS, director of the Myeloma Disease Focused Group at Stanford University, provides a reintroduction to CARTITUDE-4 and insight on how this phase 3 investigation builds on previous findings of CAR T vs standard-of-care findings in relapsed/refractory multiple myeloma (RRMM)Maryland · Maryland Read Article

Findings Reveal Gaps in Care for Pregnant Minority Women With Cancer

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.United States · United States Read Article

Safety Drives Decision to Move to Zanubrutinib in CLL

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.United States · United States Read Article

Paradigm Shift in the Management of Pulmonary Arterial Hypertension

Panelists discuss how sotatercept represents a paradigm shift as the first activin signaling inhibitor showing dramatic improvements in heavily pretreated patients, with the Stellar and Zenith trials demonstrating significant reductions in clinical worsening and potential for reverse remodeling.Read Article

Other Investigational Treatment Options for SMA

Panelists discuss how combination therapies targeting different aspects of spinal muscular atrophy (SMA), such as myostatin inhibitors (targeting muscle) alongside SMN protein-enhancing treatments, hold promise for addressing fatigue and improving muscle function in older patients.Read Article

Sotatercept for Patients with Pulmonary Arterial Hypertension

Panelists discuss how riociguat targets the nitric oxide pathway and is approved for both Group 1 PAH and Group 4 chronic thromboembolic pulmonary hypertension, with specific patient selection criteria based on risk stratification and surgical candidacy.Read Article

Breaking News Topics Related to ajmc.com